Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190903 | 1.00 | TSHR (0.38) | TSHRAOC3DRD4GAAHTR1A | |
| SCHEMBL20943374 | 0.86 | PSEN1 (0.34) | TSHRGAA | |
| SCHEMBL20943373 | 0.86 | PSEN1 (0.34) | TSHRGAA | |
| SCHEMBL8115632 | 0.81 | AOC3 (0.52) | TSHRAOC3DRD4GAAHTR1A | |
| SCHEMBL8113426 | 0.81 | AOC3 (0.52) | TSHRAOC3DRD4GAAHTR1A | |
| SCHEMBL3185372 | 0.81 | AOC3 (0.52) | TSHRAOC3DRD4GAAHTR1A | |
| SCHEMBL281883 | 0.79 | IDO1 (0.48) | — | |
| SCHEMBL282798 | 0.79 | IDO1 (0.48) | — | |
| SCHEMBL3156406 | 0.79 | IDO1 (0.48) | — | |
| SCHEMBL20868524 | 0.78 | LMNA (0.50) | TSHRAOC3HTR1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024183772-A1 | CYCLIC PHOSPHATE COMPOUND AS DRUG FOR REGULATING CHOLESTEROL METABOLISM VIA LIVER DELIVERY AND USE | 浙江柏拉阿图医药科技有限公司 | 2024-09-12 | — | — | WO | disclosed |
| EP-3476854-B1 | ANTIVIRAL PRECURSOR DRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USE THEREOF | ZHEJIANG PALOALTO PHARMACEUTICAL TECH CO LTD (CN) | 2021-05-12 | — | — | EP | disclosed |
| CN-107540710-B | Liver delivery antiviral prodrug nucleoside cyclic phosphate ester compound and application thereof | 浙江柏拉阿图医药科技有限公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10668090-B2 | Liver specific delivery-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof | ZHEJIANG PALO ALTO PHARMACEUTICALS, INC (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190125771-A1 | LIVER SPECIFIC DELIVERY-BASED ANTIVIRAL PRODRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USES THEREOF | ZHEJIANG PALO ALTO PHARMACEUTICALS,INC (CN) | 2019-05-02 | — | — | US | disclosed |
| EP-3476854-A1 | LIVER DELIVERY-BASED ANTIVIRAL PRECURSOR DRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USE THEREOF | Zhejiang Paloalto Pharmaceutical Technology Co Ltd (CN) | 2019-05-01 | — | — | EP | disclosed |
| EP-1753762-B1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | METABASIS THERAPEUTICS INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-7582758-B2 | producing cyclic phosphonic acid diesters prodrugs, used to improve the oral bioavailability; by reacting a chiral 1,3-diol and an activated phosphonic acid in the presence of a Lewis acid; Adefovir drug target delivery to liver | METABASIS THERAPEUTICS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1753762-A1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | Metabasis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005123729-A1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | METABASIS THERAPEUTICS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125771-A1 | LIVER SPECIFIC DELIVERY-BASED ANTIVIRAL PRODRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USES THEREOF | SLC10A1, NPC1, NPC1L1 | TSHR 4759/4885AOC3 2530/4885DRD4 787/4885 |
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | PHOSPHO1, LPAR1, LPAR2 | TSHR 1594/4885AOC3 1083/4885DRD4 1321/4885 |
| US-10668090-B2 | Liver specific delivery-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof | SLC10A1, NPC1, NPC1L1 | TSHR 4759/4885AOC3 2530/4885DRD4 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.